Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan

Gynecologic Oncology

Volumn 111, Issue 2, 2008, Pages 188-196

  Insinga, Ralph P ^a   Ye, Xin ^b   Singhal, Puneet K ^a   Carides, George W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Department of Health Economics and Outcomes ^*  (United States)

Author keywords

Cancer; Cervix; Cost; Resource use; Vagina; Vulva

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; OUTCOME ASSESSMENT; POPULATION DYNAMICS; PRIORITY JOURNAL; RESOURCE MANAGEMENT; UNITED STATES; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENITAL NEOPLASMS, FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INSURANCE, HEALTH; MIDDLE AGED; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 55649110885     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.07.032     Document Type: Article

References (38)

1. Denny L., and Ngan H.Y. Prevention and treatment of HPV associated disease in the HPV vaccine era. Section B: malignant manifestations of HPV infection - Carcinoma of the cervix, vulva, vagina, anus, and penis. Int J Obstet Gynecol 94 Suppl 1 (2006) S50-S55
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
4. Tyring S.K. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 189 3 Suppl (2003) S17-S23
5. Monk B.J., Burger R.A., Lin F., Parham G., Vasilev S.A., and Wilczynski S.P. Prognostic significance of human papillomavirus DNA in vulvar carcinoma. Obstet Gynecol 85 5 Pt 1 (1995) 709-715
6. Nuovo G.J., Delvenne P., MacConnell P., Chalas E., Neto C., and Mann W.J. Correlation of histology and detection of human papillomavirus DNA in vulvar cancers. Gynecol Oncol 43 3 (1991) 275-280
7. Daling J.R., Madeleine M.M., Schwartz S.M., Shera K.A., Carter J.J., McKnight B., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 84 2 (2002) 263-270
8. Kiyabu M.T., Shibata D., Arnheim N., Martin W.J., and Fitzgibbons P.L. Detection of human papillomavirus in formalin-fixed, invasive squamous carcinomas using the polymerase chain reaction. Am J Surg Pathol 13 3 (1989) 221-224
9. Merino M.J. Vaginal cancer: the role of infectious and environmental factors. Am J Obstet Gynecol 165 4 Pt 2 (1991) 1255-1262
10. *Stat. 4-16-2007. Bethesda, MD, U.S.A., Cancer Statistics Branch, National Cancer Institute, National Insititutes of Health.
11. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2002 Incidence and Mortality Web-based Report. Atlanta: U.S.Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2005.Available at: www.cdc.gov/cancer/npcr/uscs. 3-21-2007.
12. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site. 2007.
13. Brown A.D., and Garber A.M. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 281 4 (1999) 347-353
14. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100
15. Holmes J., Hemmett L., and Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. a review of recent modelling studies. Eur J Health Econ 6 1 (2005) 30-37
16. Population pyramids and demographic summary indicators for U.S. Regions and Divisions. U.S.Census Bureau (http://www.census.gov/population/www/projections/regdivpyramid.html) . 8-17-2007.
17. Comorbidity Software, Version 3.2. Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp, 2006.
18. Carides G.W., Heyse J.F., and Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 1 3 (2000) 299-313
19. Charlson M., Szatrowski T.P., Peterson J., and Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 47 11 (1994) 1245-1251
20. Hesterberg T., Monaghan S., Moore D.S., Clipson A., and Epstein R. Bootstrap Methods and Permutation Tests (2003), W. H. Freeman, New York, N.Y.
21. Lin D.Y. Linear regression analysis of censored medical costs. Biostatistics 1 1 (2000) 35-47
22. Consumer Price Index-Medical Care. U.S. Department of Labor. Bureau of Labor Statistics. 2006. http://data.bls.gov/cgi-bin/surveymost, Accessed. 2-15-2007.
23. 2000 resident population estimates of the United States by age and sex., http://wonder.cdc.gov/census.shtml. 3-15-2004. U.S. Census Bureau.
24. Newall A.T., Beutels P., Wood J.G., Edmunds W.J., and MacIntyre C.R. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7 4 (2007) 289-296
25. Baker M.S., Kessler L.G., and Smucker R.C. Site-specific treatment costs for cancer: an analysis of the Medicare continuous history sample file. In: Sheffler R.M., and Andrews N.C. (Eds). Cancer Care and Costs (1989), Health Administration Press, Ann Arbor, MI 127-138
26. Fahs M.C., Mandelblatt J., Schechter C., and Muller C. Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 117 6 (1992) 520-527
27. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 18 (2002) 2372-2381
28. Ferrante J.M., Gonzalez E.C., Roetzheim R.G., Pal N., and Woodard L. Clinical and demographic predictors of late-stage cervical cancer. Arch Fam Med 9 5 (2000) 439-445
29. Leath III C.A., Straughn Jr. J.M., Kirby T.O., Huggins A., Partridge E.E., and Parham G.P. Predictors of outcomes for women with cervical carcinoma. Gynecol Oncol 99 2 (2005) 432-436
30. Helms L.J., and Melnikow J. Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care 37 7 (1999) 652-661
31. McCrory DC, Myers ER, Nanda K, Bastian LA, Hasselblad V, Matchar DB. Evaluation of cervical cytology. Evidence report/Technology assessment No. 5. AHCPR Publication No. 99-E010. 1999. Rockville, MD, Agency for Healthcare Policy and Research.
32. Insinga R.P., Glass A.G., and Rush B.B. Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev 13 3 (2004) 355-360
33. National Center for Health Statistics. Health, United States, 2006: With Chartbook on Trends in the Health of Americans. Hyattsville, MD: 2006.
34. Yabroff K.R., Warren J.L., and Brown M.L. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 4 11 (2007) 643-656
35. Fireman B.H., Quesenberry C.P., Somkin C.P., Jacobson A.S., Baer D., West D., et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 18 4 (1997) 51-76
36. Penberthy L., McClish D., Pugh A., Smith W., Manning C., and Retchin S. Using hospital discharge files to enhance cancer surveillance. Am J Epidemiol 158 1 (2003) 27-34
37. Brown M.L., Riley G.F., Schussler N., and Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40 8 Suppl (2002) IV-17
38. Max W., Rice D.P., Sung H.Y., Michel M., Breuer W., and Zhang X. The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol 88 2 (2003) 96-103